IFNL4 and Cirrhosis: However, the SVR at 12 weeks (SVR12) rate in the 24‐week DAA only arm among patients with cirrhosis (where a clear IFNL4 effect was observed) was 79% in this study, comparable to the 80% response rate in the 16‐week arm among patients without cirrhosis (where no IFNL4 gene effect was observed).